Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 5/20 | 0.52 |
| ▸ | CPA1 | P15085 | 4/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970186 | 1.00 | MME (0.57) | MMENAALAD2BACE1ACECPA1 | |
| SCHEMBL29381316 | 0.97 | MME (0.55) | MMENAALAD2BACE1ACECPA1 | |
| SCHEMBL8821945 | 0.97 | MME (0.55) | MMENAALAD2BACE1ACECPA1 | |
| SCHEMBL30903452 | 0.96 | BACE1 (0.57) | MMENAALAD2BACE1 | |
| SCHEMBL31474554 | 0.95 | BACE1 (0.56) | MMENAALAD2BACE1 | |
| SCHEMBL30123399 | 0.94 | MME (0.51) | MMENAALAD2BACE1ACECPA1 | |
| SCHEMBL31720880 | 0.93 | BACE1 (0.61) | NAALAD2BACE1 | |
| SCHEMBL31134839 | 0.93 | BACE1 (0.57) | MMENAALAD2BACE1 | |
| SCHEMBL30307335 | 0.93 | BACE1 (0.61) | NAALAD2BACE1 | |
| SCHEMBL30206996 | 0.92 | ACE (0.57) | MMENAALAD2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| CN-119780446-A | Biomarker for milk cow early pregnancy related state and application thereof | 宁夏大学 | 2025-04-08 | — | — | CN | claimed |
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4347661-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | ImmunoGen, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4304660-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ImmunoGen, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| US-5643955-A | CARBOXYL-CONTAINING DIPEPTIDES AND DERIVATIVES (TASTANDS) TO REDUCE OR ELIMIATE A ITTER OR METALLIC TASTE; FOODS; DRUGS; ARTIFICIAL SWEETENERS; POTASSIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-07-01 | — | — | US | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
| EP-0728419-A2 | Ingestible containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0661932-A4 | SPECIFIC EATABLE TASTE MODIFIERS. | BIORESEARCH INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0661932-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1993010677-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1993-06-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | MME 1501/4885NAALAD2 1324/4885BACE1 2079/4885 |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ADAM9, TMPRSS15, ADAM17 | MME 59/4885NAALAD2 179/4885BACE1 484/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | MME 3187/4885NAALAD2 3323/4885BACE1 4264/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | MME 2240/4885NAALAD2 4066/4885BACE1 72/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | MME 961/4885NAALAD2 1932/4885BACE1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.